S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
A One Stop Shop for Everything Futures Trading (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The single greatest medical breakthrough of all time? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The single greatest medical breakthrough of all time? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
A One Stop Shop for Everything Futures Trading (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The single greatest medical breakthrough of all time? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The single greatest medical breakthrough of all time? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
A One Stop Shop for Everything Futures Trading (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The single greatest medical breakthrough of all time? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The single greatest medical breakthrough of all time? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
A One Stop Shop for Everything Futures Trading (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The single greatest medical breakthrough of all time? (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The single greatest medical breakthrough of all time? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:PGNX

Progenics Pharmaceuticals - PGNX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume
34.93 million shs
Average Volume
1.16 million shs
Market Capitalization
$355.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PGNX stock logo

About Progenics Pharmaceuticals (NASDAQ:PGNX) Stock

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PGNX Stock News Headlines

I've Got an Options Bandage for a Sick Economy
What Falling Estimates & Price Mean for Progenics (PGNX)
Lantheus Completes Merger with Progenics
Progenics Stockholders Approve Merger with Lantheus
Progenics up 11% on improved merger terms with Lantheus
Lantheus and Progenics Agree to Amended Transaction Terms
See More Headlines

Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PGNX Company Calendar

Last Earnings
5/07/2020
Today
12/01/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:PGNX
CUSIP
74318710
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

Net Income
$-68,550,000.00
Net Margins
-180.28%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$34.99 million
Book Value
$0.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$355.05 million
Optionable
Optionable
Beta
1.89

Key Executives

  • Mr. Mark R. Baker (Age 64)
    CEO & Director
  • Mr. Patrick Fabbio (Age 51)
    Exec. VP & CFO
  • Mr. Benedict Osorio (Age 62)
    Chief Operating Officer
  • Dr. Vivien Wong (Age 62)
    Exec. VP of Devel.
  • Mr. Bryce V. Tenbarge (Age 46)
    Sr. VP of Commercial













PGNX Stock - Frequently Asked Questions

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%.
Read the conference call transcript
.

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), IMAX (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), OPKO Health (OPK), Citius Pharmaceuticals (CTXR) and Dynavax Technologies (DVAX).

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.10.

How much money does Progenics Pharmaceuticals make?

Progenics Pharmaceuticals (NASDAQ:PGNX) has a market capitalization of $355.05 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The official website for the company is www.progenics.com. The biotechnology company can be reached via phone at 646-975-2500 or via email at mdowns@progenics.com.

This page (NASDAQ:PGNX) was last updated on 12/2/2022 by MarketBeat.com Staff